메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company

Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 -- LOTTE BIOLOGICS (CEO James Park) today announced that it has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company. The partnership covers a late-stage Phase 3 program that is advancing into multiple new indications, and extends to commercial supply following potential regulatory approvals. By aligning with its partner's meaningful
- 김갑성 기자
- 2025-09-02 08:00
GlobantがUnityと提携し、エンタープライズ分野におけるリアルタイム3Dイノベーションを加速

この新しいパートナーシップは、Unityの新規サービス・パートナー・プログラムを通じて、自動車、ヘルスケア、製造業など、ゲーム以外の業界に高度なインタラクティブ・テクノロジーを提供します。サンフランシスコ, 2025年9月2日 -- 革新的なテクノロジー・ソリューションを通じてビジネスを改革することに注力するデジタル・ネイティブ企業であるGlobant（NYSE：GLOB）は本日、インタラクティブな体験を創造する世界有数のプラットフォームであるUnity（NYSE：U）との新たなグローバル・パートナーシップを発表しました。この提携により、GlobantはUnityサービス・パートナー・プログラム（Unity Service Partner Program）のメンバーとなり、両社はデジタル・ツイン、自動車、ヘルスケア、ライフ・サイエンス、製造業などの急成長分野に最先端のインタラクティブ・ソリューションを提供できるようになりました。 GlobantはUnityサービス・パートナーとして、企業がUnityのリアルタイム3Dテクノロジーとデジタル・アセット管理ソリューションを活用して、製品開発を加速し、運用を最適化し、顧客エンゲージメントを強化できるよう支援します。このコラボレーションでは、製造効率を高めるためのデジ
- 황정호 기자
- 2025-09-02 08:00
IREX Board of Trustees names Aleksander Dardeli, as President and CEO

WASHINGTON, Sept. 2, 2025 -- The IREX Board of Trustees has appointed Aleksander (Aleks) Dardeli as the organization's next President and CEO, effective September 1, 2025. Aleks returns to IREX with a bold vision for the future, along with the strategic agility and steady leadership to reimagine possibilities and chart new paths forward. As a former Executive Vice President of IREX, he led the expansion of the organization's global footprint, catalyzed innovation, strengthened management systems, and oversaw the acquisition of Development Gateway, a mission-aligned venture. He
- 황정호 기자
- 2025-09-02 07:11
Aker Horizons ASA: Mandatory notification of trade

FORNEBU, Norway, Sept. 2, 2025 -- Reference is made to the announcements made today by Aker Horizons ASA (the "Company") regarding the satisfaction of the conditions for the distribution of the Company's shares in AKHH as a dividend in-kind (the "Dividend Shares") to the Company's shareholders, where each Company share entitles the owner to receive one (1) AKHH share. AKH HoldCo AS will, as a result of the distribution, receive 464,285,714 Dividend Shares. In addition, the following primary insiders (PDMRs) of the Company and close associates of PDMRs will, a
- 황정호 기자
- 2025-09-02 05:22
Aker Horizons ASA: Key information relating to payment of dividend-in-kind

FORNEBU, Norway, Sept. 2, 2025 -- Reference is made to the announcements today made by Aker Horizons ASA (the "Company" or "Aker Horizons") regarding the satisfaction of conditions for (i) completion of the merger between its subsidiary, Aker Horizons Holding AS ("AKHH"), and AKH HoldCo AS ("AKH HoldCo"), a subsidiary of Aker ASA (the "Merger") and (ii) the distribution by the Company of its shares in AKHH as a dividend in-kind in order to enable the Company's shareholders to benefit directly from the Merger consideration. Below is key
- 황정호 기자
- 2025-09-02 04:56
Aker Horizons ASA: Update on merger with Aker

FORNEBU, Norway, Sept. 2, 2025 -- Reference is made to the announcement made by Aker Horizons ASA (the "Company" or "Aker Horizons") on 9 May 2025 whereby the Company announced a merger between its subsidiary, Aker Horizons Holding AS ("AKHH"), and AKH HoldCo AS ("AKH HoldCo"), a subsidiary of Aker ASA (the "Merger"). Reference is also made to the extraordinary general meeting in the Company held on 6 June 2025 ("EGM") where it among other things was resolved to distribute all of the Company's shares in AKHH as a dividend in-kind (th
- 황정호 기자
- 2025-09-02 04:53
Aker Horizons ASA: Disclosure of large shareholdings and mandatory notification of trade

FORNEBU, Norway, Sept. 2, 2025 -- Reference is made to the announcements made by Aker Horizons ASA (the "Company") on 9 May 2025 regarding the planned merger between the Company's subsidiary, Aker Horizons Holding AS ("AKHH"), and AKH HoldCo AS ("AKH HoldCo"), a subsidiary of Aker ASA (the "Merger"). As a preparatory step for completion of the Merger, Aker Capital AS has today transferred all of its 464,285,714 shares in the Company, representing approximately 67.25 per cent of the Company's share capital, to AKH HoldCo. Pursuant to the No
- 황정호 기자
- 2025-09-02 04:39
CMEF 2025: 의료 및 보건 산업의 전방위적ㆍ고품질 발전 촉진

[ 메디채널 김갑성 기자 ] 광저우, 중국 2025년 9월 1일 -- 제92회 중국국제의료기기박람회(China International Medical Equipment Fair, CMEF 2025) 하반기(가을) 행사가 9월 26일부터 29일까지 광저우 중국수출입상품교역전시관(China Import and Export Fair Complex, 캔톤 페어 전시장)에서 열릴 예정이다. '건강, 혁신, 협업(Health, Innovation, Collaboration)'을 주제로 한 이번 박람회는 글로벌 헬스케어 업계를 한자리에 모아 고품질 개발을 위한 새로운 기회를 모색한다. CMEF는 국제 최고 수준의 전시회로서 업계 전반의 전 세계 이해관계자를 결집시키며 혁신 기술 전시, 파트너십 및 브랜드 협력, 학술 교류, 트렌드 인사이트, 교육을 통해 글로벌 헬스케어의 고품질 성장을 견인한다. CMEF 2025는 약 20만㎡ 규모로 열리며 약 4000개 기업과 12만 명의 전문가가 참가할 예정이다. 이번 박람회는 의료 영상, 체외 진단, 수술 로봇, 스마트 헬스케어 등 28개 테마 존을 구성해, 연구개발부터 최종 사용자 응용
- 김갑성 기자
- 2025-09-01 21:50
Norma Completes Quantum AI Algorithm Validation on NVIDIA

[ 메디채널 김갑성 기자 ] "Quantum AI up to 73x Faster on NVIDIA CUDA-Q" Norma, a quantum computing company, has validated the performance of quantum AI algorithms using NVIDIA CUDA-Q. By running these algorithms for drug development on CUDA-Q, Norma observed computational speeds up to 73 times faster. The company has secured use cases for quantum AI in drug development and plans to expand validation efforts into various fields. SEOUL, South Korea, Sept. 1, 2025 -- Quantum computing company Norma (CEO Hyunchul Jung, www.norma.co.kr) has achieved over 73× faster
- 김갑성 기자
- 2025-09-01 21:00
AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction

AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the Paradigm of Submental Fat Reduction SEOUL, South Korea, Sept. 1, 2025 -- AMI Pharm's novel injectable drug, AYP-101, has shown promising results in a Phase 2 clinical trial for the reduction of submental fat (SMF), commonly known as a double chin. The clinical data from the trial was recen
- 김갑성 기자
- 2025-09-01 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-03_WED

2025-09-02_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 03일 08시 00분